- Education
-
Research
Current research
Talent
-
Collaboration
Businesses
Government agencies and institutions
Alumni
-
About AU
Organisation
Job at AU
Long-term management of osteoporosis
2021.02.11 |
| Date | Fri 26 Feb |
| Time | 14:00 — 16:00 |
| Location | Online via Zoom |
On Friday 26 February at 14.00, Anne Sophie Sølling defends her PhD dissertation "Long-term management of osteoporosis".
Discontinuing denosumab is associated with a rapid bone loss, why treatment is considered to be lifelong. In a 2-year study including 61 patients it is investigated if treatment with zoledronate could prevent this bone loss. The study finds that treatment with zoledronate after discontinuation of denosumab is not able to completely prevent bone loss at the spine or hip.
It is clinical practice to consider alendronate discontinuation after 5 years in patients without any fractures during treatment and a DXA scan finds improvement. In a 2-year study with 142 patients discontinuing alendronate it is investigated if biochemical bone turnover markers could predict bone loss after 1 and 2 years. The project was not able to identify an algorithm predicting bone loss in the individual patient based on bone turnover markers.
The summary is written by the PhD student.
The defence is public and takes place online. Please read the attached press release for more information.
PhD student Anne Sophie Sølling
Mail: annesoel@rm.dk
Phone: (+45) 22300524